Trials / Active Not Recruiting
Active Not RecruitingNCT05469789
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
Demographic and Clinical Characteristics, Treatment Patterns, and Real-world Effectiveness of Lanadelumab in Patients With Hereditary Angioedema Type I or II in the United Kingdom: an Ambispective Cohort Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to compare the HAE attacks (both total and those requiring on-demand treatment) in the 12 months before and up to 24 months after initiation of treatment with lanadelumab. This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | As it is an observational study, no intervention is administered in this study. |
Timeline
- Start date
- 2023-06-29
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2022-07-22
- Last updated
- 2025-11-20
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05469789. Inclusion in this directory is not an endorsement.